AstraZeneca Enters Deal With CSPC Pharma Valued at Up to $5.33 Billion

AstraZeneca just inked a major deal with China’s CSPC Pharmaceuticals—potentially worth up to $5.33 billion—to turbocharge drug discovery using AI. The partnership will focus on finding and developing new medicines faster, leveraging CSPC’s research muscle and AstraZeneca’s global reach.